Plant Name: Aralia continentalis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| TSHR; | |
| PTPN1; PTPN2; ACP1; PTPRF; CDC25B; | |
| RECQL; PLA2G1B; HPGD; HSD11B1; AKR1B10; AKR1B1; GFER; HSD17B10; ALDH1A1; POLB; | |
| ACHE; | |
| MAPK1; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA5A; CA6; | |
| RORC; | |
| NR1H4; | |
| CASP1; CASP7; | |
| NFKB1; | |
| NPC1; XPO1; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | XPO1 | Exportin-1 | O14980 | CHEMBL5661 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.120E-14 | 2.675E-10 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.152E-13 | 5.017E-10 | AKR1B1, AKR1B10, APP, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HSD11B1, NPC1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.275E-13 | 8.257E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.082E-12 | 2.944E-09 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.975E-11 | 5.398E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 9.359E-11 | 1.456E-07 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.569E-10 | 7.133E-07 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.534E-10 | 9.114E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.710E-09 | 3.663E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4, RORC |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.435E-09 | 6.848E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.058E-08 | 7.432E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.818E-08 | 2.375E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 4.501E-08 | 2.579E-05 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.960E-08 | 2.769E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.659E-07 | 7.853E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 3.325E-07 | 1.393E-04 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.135E-06 | 4.493E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 2.338E-06 | 8.484E-04 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 4.616E-06 | 1.523E-03 | CYP2A13, CYP2A6 |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 5.782E-06 | 1.851E-03 | AKR1B1, AKR1B10, HPGD, HSD11B1, HSD17B10 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.132E-06 | 2.187E-03 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9, NR1H4, PTPN1, RORC |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 8.856E-06 | 2.606E-03 | CA2, CA7, MAPK1, NPC1, NR1H4, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 9.756E-06 | 2.833E-03 | AKR1B1, CA2, CA9, CYP1A2, HPGD, NFKB1, NPC1, PLA2G1B, TSHR |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.383E-05 | 3.672E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 3.672E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.383E-05 | 3.672E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.383E-05 | 3.672E-03 | GPBAR1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.995E-05 | 5.172E-03 | CA2, CA9, CASP1, CYP1A2, HPGD, NFKB1, NPC1, NR1H4, RORC |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 2.685E-05 | 6.718E-03 | AKR1B1, APP, CA12, CA2, CA7, MAPK1, NPC1, NR1H4, PLA2G1B, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 2.745E-05 | 6.718E-03 | AKR1B1, AKR1B10, ALDH1A1, APP, CYP3A4, NPC1 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.762E-05 | 6.718E-03 | PTPN1, PTPN2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.603E-05 | 8.346E-03 | CYP3A4, NPC1, NR1H4, RORC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.565E-18 | 3.408E-14 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.464E-18 | 6.384E-16 | CA12; CA1; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.566E-10 | 1.120E-08 | HSD11B1; CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.603E-10 | 1.718E-08 | HSD11B1; CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.423E-09 | 1.837E-07 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.652E-09 | 1.306E-07 | CYP2C9; PLA2G1B; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.403E-07 | 5.727E-06 | CYP2C9; CYP2A6; CYP1A2; ALDH1A1; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.630E-06 | 7.416E-05 | CYP2C9; APP; CYP2D6; MAPK1; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.551E-05 | 5.078E-04 | HSD11B1; CYP2C9; CYP2A6; AKR1B10; PLA2G1B; CYP1A2; ALDH1A1; AKR1B1; CYP2C19; CYP3A4; HSD17B10 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.737E-05 | 2.912E-04 | PTPN1; MAPK1; ACP1; PTPRF |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.832E-05 | 2.912E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.094E-04 | 2.495E-03 | CASP7; CASP1; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 4.891E-04 | 3.885E-03 | XPO1; CASP1; MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.988E-04 | 2.848E-03 | CYP2C9; PLA2G1B; CYP2C19 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.192E-04 | 3.747E-03 | APP; CASP7; MAPK1; HSD17B10 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.328E-04 | 2.504E-03 | CASP1; MAPK1; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.452E-04 | 2.504E-03 | HSD11B1; CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.456E-04 | 3.749E-03 | CA2; NR1H4; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.590E-03 | 1.083E-02 | CASP7; MAPK1; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.549E-03 | 1.083E-02 | PTPN1; NFKB1; PTPRF |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.807E-04 | 5.876E-03 | CASP1; MAPK1; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.156E-03 | 1.736E-02 | CASP7; MAPK1; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.093E-03 | 1.736E-02 | PTPN1; MAPK1; PTPRF |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.376E-03 | 3.567E-02 | MAPK1; NFKB1; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.082E-03 | 3.711E-02 | POLB; MAPK1; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.387E-03 | 3.262E-02 | MAPK1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.196E-02 | 4.276E-02 | PLA2G1B; MAPK1; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 6.829E-03 | 3.367E-02 | AKR1B10; AKR1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.482E-03 | 3.567E-02 | MAPK1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 8.236E-03 | 3.567E-02 | RORC; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.003E-02 | 3.775E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.030E-02 | 3.775E-02 | MAPK1; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 7.993E-03 | 3.567E-02 | CASP1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.030E-02 | 3.775E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 8.236E-03 | 3.567E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.030E-02 | 3.775E-02 | MAPK1; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.203E-03 | 2.226E-02 | CYP2A6; CYP3A4 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.804E-03 | 1.173E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.592E-03 | 1.545E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.052E-03 | 1.276E-02 | AKR1B10; AKR1B1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.288E-05 | 5.574E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1; AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; NFKB1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | XPO1; CA9; MAPK1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | XPO1; CA1; CA9; MAPK1; NFKB1; ACHE; CDC25B; APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1; PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |